about
A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humansAdvanced vaccine candidates for Lassa feverEnvelope exchange for the generation of live-attenuated arenavirus vaccinesRodent-borne diseases and their risks for public healthA live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses.A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.Lassa fever: epidemiology, clinical features, and social consequences.Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverageCoverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model systemIdentification of protective Lassa virus epitopes that are restricted by HLA-A2.Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to manEnhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunityLassa virus.Viral zoonoses in Europe.Vaccine Platforms to Control Arenaviral Hemorrhagic FeversA historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infectionMucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever.The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex.Arenavirus evasion of host anti-viral responses.Immune responses and Lassa virus infection.Molecular Mechanism for LAMP1 Recognition by Lassa Virus.Structure-function relationship of the mammarenavirus envelope glycoprotein.Arenavirus entry occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic mechanism.A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.
P2860
Q24611383-B55A85FF-1860-483A-84BB-23959B8B614DQ26823627-E594EDE3-B5ED-486F-B66F-E8308E9EBDE0Q27320211-3F346FD2-7A78-47D8-8AA4-FEA824245174Q28249580-7F3ADA8B-44FB-46FB-A420-B9E4276DF744Q33226128-E803FFAD-1361-4535-BF60-C93BEDAB02E7Q33519507-B41B80E5-00B1-495A-9454-534D96395F85Q33822092-85D58227-2416-475A-9730-21CFF4C6876EQ33892499-8B5D432D-BD3B-430A-B1AB-6B77AFB9CE41Q33909096-6FDD247D-913A-4DE6-90D7-F4A7B25B1E8DQ35024149-6F110BA0-37D9-4C96-A97E-BEC2DF38A928Q35248863-676E36B5-6E03-4A66-AC4F-5FA1C199E519Q35826698-5964A025-20AE-4A9D-8F86-7E72D7B04284Q35842756-51E9D129-7FE5-4D12-8118-85EA32EA7F9BQ35919691-A0542D04-E255-4644-ABF4-B64B2D31A033Q36197670-2EDE7EAE-FA41-405C-B3D4-F4062117F3CAQ36612929-18B764F5-9103-44ED-8301-75DAFDA8E192Q36641764-E2630115-A44A-468F-9AD1-644B522431A9Q36925354-E33C02C0-97BF-4110-8346-9D242E9244FFQ37511518-99E3E913-5C6E-4590-9E8D-A8BCB9841180Q38064279-A9F0779B-91CF-4DFA-B8C6-551953802EF2Q38064284-635D87C8-236B-493B-98FE-E9F4771E87C5Q38875186-5AE876E3-5442-4B55-B23E-2DFCF4FA36E1Q38937488-D85F7345-D19A-4EA8-B846-2A2E49DAE108Q40094400-290C2EAB-F12C-4854-8BBC-D0A4FCBB21C4Q46768300-8152B915-1ED9-4F58-A558-C8FD6D7DBAFB
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Towards a human Lassa fever vaccine.
@ast
Towards a human Lassa fever vaccine.
@en
Towards a human Lassa fever vaccine.
@nl
type
label
Towards a human Lassa fever vaccine.
@ast
Towards a human Lassa fever vaccine.
@en
Towards a human Lassa fever vaccine.
@nl
prefLabel
Towards a human Lassa fever vaccine.
@ast
Towards a human Lassa fever vaccine.
@en
Towards a human Lassa fever vaccine.
@nl
P2860
P356
P1476
Towards a human Lassa fever vaccine.
@en
P2093
Fisher-Hoch SP
McCormick JB
P2860
P304
P356
10.1002/RMV.329
P577
2001-09-01T00:00:00Z